Excessive Daytime Somnolence Associated with Parkinson’s Disease

  • James Battista
  • Renee MondererEmail author
  • Michael Thorpy


Excessive daytime sleepiness (EDS) occurs in up to 50 % of patients with Parkinson’s disease (PD) and is characterized by an inability to maintain full alertness in the daytime and undesirable lapses into sleep. Often overshadowed by the motor symptoms of PD, EDS can contribute to home and automobile accidents and have a negative impact on mood and overall quality of life. Sleep disturbances and EDS can result from the medications used to treat PD, degeneration of neuronal systems involved in the control of the sleep–wake system that occurs as part of the PD disease process, and comorbid conditions including specific sleep disorders and depression. The treatment of EDS in the PD patient requires careful evaluation of the multiple contributing causes and instituting recommendations that can consist of sleep hygiene and behavioral changes, alterations in the dosing and timing of PD medications, treatment of comorbid disorders, and the use of medications that affect nocturnal sleep quality and daytime alertness.


Deep Brain Stimulation Daytime Sleepiness Epworth Sleepiness Scale Excessive Daytime Sleepiness Sodium Oxybate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Ghorayeb I, Loundou A, Auquier P, et al. A nationwide survey of excessive daytime sleepiness in Parkinson’s disease in France. Mov Disord. 2007;22:1567–72.CrossRefPubMedGoogle Scholar
  2. 2.
    Breen DP, Williams-Gray CH, Mason SL, et al. Excessive daytime sleepiness and its risk factors in incident Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2013;84:233–4.CrossRefPubMedGoogle Scholar
  3. 3.
    Boddy F, Rowan EN, Lett D, et al. Subjectively reported sleep quality and excessive daytime somnolence in Parkinson’s disease with and without dementia, dementia with Lewy bodies and Alzheimer’s disease. Int J Geriatr Psychiatry. 2007;22:529–35.CrossRefPubMedGoogle Scholar
  4. 4.
    Ondo WG, Dat Vuong K, Khan H, et al. Daytime sleepiness and other sleep disorders in Parkinson’s disease. Neurology. 2001;57:1392–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Arnulf I, Leu-Semenescu S. Sleepiness in Parkinson’s disease. Parkinsonism Relat Disord. 2009;15 Suppl 3:S101–4.CrossRefPubMedGoogle Scholar
  6. 6.
    Manni R, Terzaghi M, Sartori I, et al. Dopamine agonists and sleepiness in PD: review of the literature and personal findings. Sleep Med. 2003;5:189–93.CrossRefGoogle Scholar
  7. 7.
    Rissling I, Körner K, Geller F, et al. Preprohypocretin polymorphism in Parkinson’s disease patients reporting “sleep attacks”. Sleep. 2005;28:871–5.PubMedGoogle Scholar
  8. 8.
    Meindorfner C, Korner Y, Moller JC, et al. Driving in Parkinson’s disease: mobility, accidents, and sudden onset of sleep at the wheel. Mov Disord. 2005;20:832–42.CrossRefPubMedGoogle Scholar
  9. 9.
    Uc EY, Rizzo M, Anderson SW, et al. Driving with distraction in Parkinson’s disease. Neurology. 2006;67:1774–80.CrossRefPubMedGoogle Scholar
  10. 10.
    Brunner H, Wetter TC, Hogl B, et al. Microstructure of the non-rapid eye movement sleep electroencephalogram in patients with newly diagnosed Parkinson’s disease: effects of dopaminergic treatment. Mov Disord. 2002;17:928–33.CrossRefPubMedGoogle Scholar
  11. 11.
    Friedman A. Sleep pattern in Parkinson’s disease. Acta Med Pol. 1980;21:193–9.PubMedGoogle Scholar
  12. 12.
    Scaglione C, Vignatelli L, Plazzi G, et al. REM sleep behavior disorder in Parkinson’s disease: a questionnaire-based study. Neurol Sci. 2005;25:316–21.CrossRefPubMedGoogle Scholar
  13. 13.
    Wetter TC, Trenkwalder C, Gershanik O, et al. Polysomnographic measures in Parkinson’s disease: a comparison between patients with and without REM sleep disturbances. Wien Klin Wochenschr. 2001;113:249–53.PubMedGoogle Scholar
  14. 14.
    Shpirer I, Minovitz A, Klein C, et al. Excessive daytime sleepiness in patients with Parkinson’s disease: a polysomnography study. Mov Disord. 2006;21:1432–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Rye D, Bliwise DL, Dihenia B, et al. Daytime sleepiness in Parkinson’s disease. J Sleep Res. 2000;9:63–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Nass A, Nass RD. Actigraphic evidence for night-time hyperkinesias in Parkinson’s disease. Int J Neurosci. 2008;118:291–310.CrossRefPubMedGoogle Scholar
  17. 17.
    Amara A, Ray R, Walker H. The effects of deep brain stimulation on sleep in Parkinson’s disease. Ther Adv Neurol Disord. 2011;4(1):15–24.CrossRefPubMedCentralPubMedGoogle Scholar
  18. 18.
    Fronczek R, Overeem S, Lee SY, et al. Hypocretin (orexin) loss in Parkinson’s disease. Brain. 2007;130:1577–85.CrossRefPubMedGoogle Scholar
  19. 19.
    Wienecke M, Werth E, Poryazove R, et al. Progressive dopamine and hypocretin deficiencies in Parkinson’s disease: is there an impact on sleep and wakefulness? J Sleep Res. 2012;21:710–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Yasui K, Inoue Y, Kanbayashi T, et al. CSF orexin levels in Parkinson’s disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci. 2006;250:120–3.CrossRefPubMedGoogle Scholar
  21. 21.
    Zoltoski RK, Velazquez-Moctezuma J, Shiromani PJ, et al. The relative effects of selective M1 muscarinic antagonists on rapid eye movement sleep. Brain Res. 1993;608:186–90.CrossRefPubMedGoogle Scholar
  22. 22.
    Garcia-Borreguero D, Caminero AB, de la Llave Y, et al. Decreased phasic EMG activity during rapid eye movement sleep in treatment of naive Parkinson’s disease: effects of treatment with levodopa and progression of illness. Mov Disord. 2002;17:934–41.CrossRefPubMedGoogle Scholar
  23. 23.
    Rye DB. Parkinson’s disease and RLS: the dopaminergic bridge. Sleep Med. 2004;5:317–28.CrossRefPubMedGoogle Scholar
  24. 24.
    Gjerstad MD, Alves G, Wentzel-Larsen T, et al. Excessive daytime sleepiness in Parkinson’s disease: is it the drugs or the disease? Neurology. 2006;6:853–8.CrossRefGoogle Scholar
  25. 25.
    Kaynak D, Kiziltan G, Kaynak H, et al. Sleep and sleepiness in patients with Parkinson’s disease before and after dopaminergic treatment. Eur J Neurol. 2005;12:199–207.CrossRefPubMedGoogle Scholar
  26. 26.
    Razmy A, Lang AE, Shapiro CM. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson’s disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol. 2004;61:97–102.CrossRefPubMedGoogle Scholar
  27. 27.
    Ghys L, Surmann E, Whitesides J, et al. Effect of rotigotine on sleep and quality of life in Parkinson’s disease patients: post hoc analysis of RECOVER patient who were symptomatic at baseline. Expert Opin Pharmacother. 2011;12(13):1985–98.CrossRefPubMedGoogle Scholar
  28. 28.
    Trenkwalder C, Kies B, Rudzinska M, et al., Recover Study Group. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebocontrolled study (RECOVER). Mov Disord. 2011;26(1):90–9.Google Scholar
  29. 29.
    Kurth MC, Adler CH, Hilaire MS, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson’s disease experiencing motor fl uctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology. 1997;48:81–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Hublin C, Partinen M, Heinonen EH, et al. Selegiline in the treatment of narcolepsy. Neurology. 1994;44:2095–101.CrossRefPubMedGoogle Scholar
  31. 31.
    Hoy S, Keating G. Rasagiline: a review of its use in the treatment of idiopathic Parkinson’s disease. Drugs. 2012;72(5):643–69.CrossRefPubMedGoogle Scholar
  32. 32.
    Peppe A, Pierantozzi M, Alamonte V, et al. Deep brain stimulation of pedunculopontine tegmental nucleus: role in sleep modulation in advanced Parkinson’s disease patients: one-year follow-up. Sleep. 2012;35(12):1637–42.PubMedCentralPubMedGoogle Scholar
  33. 33.
    Braga-Neto P, da Silva-Junior FP, Sueli Monte F, et al. Snoring and excessive daytime sleepiness in Parkinson’s disease. J Neurol Sci. 2004;217:41–5.CrossRefPubMedGoogle Scholar
  34. 34.
    Arnulf I, Konofal E, Merino-Andreu M, et al. Parkinson’s disease and sleepiness; an integral part of PD. Neurology. 2002;58:1019–24.CrossRefPubMedGoogle Scholar
  35. 35.
    Steffen A, Hagenah J, Graefe H, et al. Obstructive sleep apnea in patients with Parkinson’s disease – report of two cases and review. Laryngorhinootologie. 2008;87:107–11.CrossRefPubMedGoogle Scholar
  36. 36.
    Gjerstad MD, Wentzel-Larsen T, Aarsland D, et al. Insomnia in Parkinson’s disease: frequency and progression over time. J Neurol Neurosurg Psychiatry. 2007;78:476–9.CrossRefPubMedCentralPubMedGoogle Scholar
  37. 37.
    Nomura T, Inoue Y, Miyake M, et al. Prevalence and clinical characteristics of restless legs syndrome in Japanese patients with Parkinson’s disease. Mov Disord. 2006;21:380–4.CrossRefPubMedGoogle Scholar
  38. 38.
    Happe S, Pirker W, Kloch G, et al. Periodic leg movements in patients with Parkinson’s disease are associated with reduced striatal dopamine transporter binding. J Neurol. 2003;250:83–6.CrossRefPubMedGoogle Scholar
  39. 39.
    Postuma RB, Bertand JA, Montplaisir J. Rapid eye movements sleep behavior disorder and risk of dementia in Parkinson’s disease: a prospective study. Mov Disord. 2012;27:720–6.CrossRefPubMedGoogle Scholar
  40. 40.
    Shulman LM, Taback RL, Rabinstein AA, et al. Non-recognition of depression and other non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord. 2002;8:193–7.CrossRefPubMedGoogle Scholar
  41. 41.
    Barnes J, Connelly V, Wiggs L, et al. Sleep patterns in Parkinson’s disease patients with visual hallucinations. Int J Neurosci. 2010;120(8):564–9.CrossRefPubMedGoogle Scholar
  42. 42.
    Rye D. Excessive daytime sleepiness and Unintended sleep in parkinson’s disease. Curr Neurol Neurosci Rep. 2006;6:169–76.CrossRefPubMedGoogle Scholar
  43. 43.
    Fernandez HH, Trieschmann ME, Burke MA, et al. Long-term outcome of quetiapine use for psychosis among parkinsonian patients. Mov Disord. 2003;18:510–4.CrossRefPubMedGoogle Scholar
  44. 44.
    Lokk J. Daytime sleepiness in elderly PD patients and treatment with the psychostimulant modafinil: a preliminary study. Neuropsychiatr Dis Treat. 2010;6:93–7.CrossRefPubMedCentralPubMedGoogle Scholar
  45. 45.
    Ondo WG, Fayle R, Atassi F, et al. Modafi nil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled prallel trial. J Neurol Neruosurg Psychiatry. 2005;76:1636–9.CrossRefGoogle Scholar
  46. 46.
    Yang H, Petrini M. Effect of cognitive behavior therapy on sleep disorder in Parkinson’s disease in China: a pilot study. Nurs Health Sci. 2012;14(4):458–63.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2015

Authors and Affiliations

  • James Battista
    • 1
  • Renee Monderer
    • 1
    Email author
  • Michael Thorpy
    • 1
  1. 1.Department of NeurologyMontefiore Medical CenterBronxUSA

Personalised recommendations